Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG
Hersch SM, Gevorkian S, Marder K, Moskowitz C, Feigin A, Cox M, Como P, Zimmerman C, Lin M, Zhang L, Ulug AM, Beal MF, Matson W, Bogdanov M, Ebbel E, Zaleta A, Kaneko Y, Jenkins B, Hevelone N, Zhang H, Yu H, Schoenfeld D, Ferrante R, Rosas HD
Neurology · 218 citas
Etiquetas de revisión
Solo mecanismosDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Solo mecanismos
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- National Institute of Neurological Disorders and Stroke
- Gobierno
- National Center for Research Resources
- Gobierno
- National Center for Complementary and Integrative Health
- Gobierno
- NCRR NIH HHS
- Gobierno
- NINDS NIH HHS
- Gobierno
- NCCIH NIH HHS
- Subvenciones
- National Institute of Neurological Disorders and Stroke (NS042861); National Center for Complementary and Integrative Health (AT00613); National Institute of Neurological Disorders and Stroke (NS 35255); National Center for Research Resources (M01-RR01066); National Center for Research Resources (M01 RR00645)
Según 6 financiadores declarados.
Publicación
- Publicado
- 2006-01-24 · Neurology · vol. 66 · número 2 · págs. 250–252
- Editorial
- Lippincott Williams & Wilkins
- Citado
- 312 citas · más que el 99% de estudios similares · 8.2× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 10 trabajos
- Acceso
- De pago
- Áreas de investigación
- Genetic Neurodegenerative Diseases · Metabolism and Genetic Disorders · Biochemical effects in animals
- Palabras clave
- creatine, Huntington's disease, 8-hydroxy-2'-deoxyguanosine, oxidative DNA damage, drug safety and tolerability, neuroprotection
- MeSH
- brain, humans, huntington disease, creatine, deoxyguanosine, double-blind method, biological availability, adult, middle aged, female, male, biomarkers, 8-hydroxy-2'-deoxyguanosine
24 autores
- Steven M. Hersch🇺🇸Harvard University; Massachusetts General Hospital; Athinoula A. Martinos Center for Biomedical Imaging
- Sona Gevorkian🇺🇸Harvard University; Massachusetts General Hospital; Athinoula A. Martinos Center for Biomedical Imaging
- Karen S. Marder🇺🇸Harvard University; Massachusetts General Hospital; Athinoula A. Martinos Center for Biomedical Imaging
- Carol Brown Moskowitz🇺🇸Harvard University; Massachusetts General Hospital; Athinoula A. Martinos Center for Biomedical Imaging
- Andrew Feigin🇺🇸Harvard University; Massachusetts General Hospital; Athinoula A. Martinos Center for Biomedical Imaging
- M. Cox🇺🇸Harvard University; Massachusetts General Hospital; Athinoula A. Martinos Center for Biomedical Imaging
- Peter G. Como🇺🇸Harvard University; Massachusetts General Hospital; Athinoula A. Martinos Center for Biomedical Imaging
- C. Zimmerman🇺🇸Harvard University; Massachusetts General Hospital; Athinoula A. Martinos Center for Biomedical Imaging
- M. T. Lin🇺🇸Harvard University; Massachusetts General Hospital; Athinoula A. Martinos Center for Biomedical Imaging
- L. Zhang🇺🇸Harvard University; Massachusetts General Hospital; Athinoula A. Martinos Center for Biomedical Imaging
- Aziz Müfit Uluğ🇺🇸Harvard University; Massachusetts General Hospital; Athinoula A. Martinos Center for Biomedical Imaging
- M. F. Beal🇺🇸Harvard University; Massachusetts General Hospital; Athinoula A. Martinos Center for Biomedical Imaging
- Wayne R. Matson🇺🇸Harvard University; Massachusetts General Hospital; Athinoula A. Martinos Center for Biomedical Imaging
- Mikhail B. Bogdanov🇺🇸Harvard University; Massachusetts General Hospital; Athinoula A. Martinos Center for Biomedical Imaging
- Erika N. Ebbel🇺🇸Harvard University; Massachusetts General Hospital; Athinoula A. Martinos Center for Biomedical Imaging
- Alexandra Katherine Zaleta🇺🇸Harvard University; Massachusetts General Hospital; Athinoula A. Martinos Center for Biomedical Imaging
- Y. Kaneko🇺🇸Harvard University; Massachusetts General Hospital; Athinoula A. Martinos Center for Biomedical Imaging
- Bruce G. Jenkins🇺🇸Harvard University; Massachusetts General Hospital; Athinoula A. Martinos Center for Biomedical Imaging
- Nathanael D. Hevelone🇺🇸Harvard University; Massachusetts General Hospital; Athinoula A. Martinos Center for Biomedical Imaging
- H. Zhang🇺🇸Harvard University; Massachusetts General Hospital; Athinoula A. Martinos Center for Biomedical Imaging
- Hua Yu🇺🇸Harvard University; Massachusetts General Hospital; Athinoula A. Martinos Center for Biomedical Imaging
- David Schoenfeld🇺🇸Harvard University; Massachusetts General Hospital; Athinoula A. Martinos Center for Biomedical Imaging
- Robert J. Ferrante🇺🇸Harvard University; Massachusetts General Hospital; Athinoula A. Martinos Center for Biomedical Imaging
- Herminia Diana Rosas🇺🇸Harvard University; Massachusetts General Hospital; Athinoula A. Martinos Center for Biomedical Imaging
Resumen
El texto original del estudio, en el idioma en que se publicó.
In a randomized, double-blind, placebo-controlled study in 64 subjects with Huntington disease (HD), 8 g/day of creatine administered for 16 weeks was well tolerated and safe. Serum and brain creatine concentrations increased in the creatine-treated group and returned to baseline after washout. Serum 8-hydroxy-2'-deoxyguanosine (8OH2'dG) levels, an indicator of oxidative injury to DNA, were markedly elevated in HD and reduced by creatine treatment.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.